- As recommended by the independent Data Monitoring Committee, BeiGene (BGNE +1.8%) has announced interim data from Phase 3 (RATIONALE 303) trial evaluating tislelizumab versus docetaxel in the second- or third-line setting in patients with locally advanced or metastatic non-small cell lung cancer who progressed on prior platinum-based chemotherapy.
- The 805-study met its primary endpoint of overall survival (OS) in the intention-to-treat patient population.
- Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.
- https://seekingalpha.com/news/3637202-beigenes-tislelizumab-meets-os-endpoint-in-interim-analysis-of-lung-cancer-study
Tuesday, November 17, 2020
BeiGene's tislelizumab meets OS endpoint in interim analysis of lung cancer study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.